Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality business Quality Strong, Valuation Fairly Valued, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Alkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Specialising in generics and speciality pharmaceuticals, Alkem manufactures and markets pharmaceutical generics, formulations and nutraceuticals across India and global markets.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).
Ranks #12 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 29 Mar 2022 | Deepak Kumar Singh | Employee / designated person | Sell | 0 | ₹0 |
| 8 Mar 2022 | Mritunjay Kumar Singh | Director | Buy | 0 | ₹0 |
| 8 Mar 2022 | Mritunjay Kumar Singh | Director | Buy | 0 | ₹0 |
| 25 Feb 2022 | Dhananjay and Madhurima Singh Trust | Promoter | Buy | 0 | ₹0 |
| 23 Feb 2022 | Dhananjay and Madhurima Singh Trust | Promoter | Buy | 0 | ₹0 |
| 30 Dec 2021 | Deepak Kumar Singh | Employee / designated person | Sell | 0 | ₹0 |
| 27 Dec 2021 | Deepak Kumar Singh | Employee / designated person | Sell | 0 | ₹0 |
| 23 Dec 2021 | Deepak Kumar Singh | Employee / designated person | Sell | 0 | ₹0 |
| 2 Dec 2021 | Jayanti Sinha | Promoter group | Sell | 0 | ₹0 |
| 18 Nov 2021 | Deepak Kumar Singh | Employee / designated person | Sell | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 2 Jun 2026 | SOCIETE GENERALE | Block | Buy | 48,090 | 5200.0000 | NSE |
| 2 Jun 2026 | SAMPRADA&NANHAMATI SINGH FAMILY TRUST | Block | Sell | 550,000 | 5200.0000 | NSE |
| 2 Jun 2026 | NIPPON INDIA MUTUAL FUND | Block | Buy | 48,090 | 5200.0000 | NSE |
| 2 Jun 2026 | MORGAN STANLEY ASIA SINGAPORE PTE | Block | Buy | 48,090 | 5200.0000 | NSE |
| 2 Jun 2026 | JAYANTI SINHA | Block | Sell | 1,238,220 | 5200.0000 | NSE |
| 2 Jun 2026 | ICICI PRUDENTIAL MUTUAL FUND | Block | Buy | 903,527 | 5200.0000 | NSE |
| 2 Jun 2026 | HDFC MUTUAL FUND | Block | Buy | 509,615 | 5200.0000 | NSE |
| 2 Jun 2026 | GOLDMAN SACHS BANK EUROPE SE | Block | Buy | 48,090 | 5200.0000 | NSE |
| 2 Jun 2026 | EDELWEISS MUTUAL FUND | Block | Buy | 48,090 | 5200.0000 | NSE |
| 2 Jun 2026 | DSP MUTUAL FUND | Block | Buy | 86,538 | 5200.0000 | NSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 7 Aug 2026 | Dividend - Rs 10 Per Share | 10.0000 | 7 Aug 2026 |
| 20 Feb 2026 | Interim Dividend - Rs 43 Per Share | 43.0000 | 20 Feb 2026 |
| 8 Aug 2025 | Dividend - Rs 8 Per Share | 8.0000 | 8 Aug 2025 |
| 14 Feb 2025 | Interim Dividend - Rs 37 Per Share | 37.0000 | 14 Feb 2025 |
| 9 Aug 2024 | Dividend - Rs 5 Per Share | 5.0000 | 10 Aug 2024 |
| 16 Feb 2024 | Interim Dividend - Rs 35 Per Share | 35.0000 | 17 Feb 2024 |
| 10 Aug 2023 | Dividend - Rs 10 Per Share | 10.0000 | 10 Aug 2023 |
| 17 Feb 2023 | Interim Dividend - Rs 15 Per Share & Special Dividend Rs 25 Per Share | 15.0000 | 18 Feb 2023 |
| 8 Aug 2022 | Dividend - Rs 4 Per Share | 4.0000 | 10 Aug 2022 |
| 10 Feb 2022 | Interim Dividend - Rs 30 Per Sh | 30.0000 | 12 Feb 2022 |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 14 Aug 2026 | Financial Results | Yes |
| 28 May 2026 | Financial Results/Dividend | Yes |
| 13 Feb 2026 | Financial Results/Dividend | Yes |
| 13 Nov 2025 | Financial Results | Yes |
| 12 Aug 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.
Part of: NIFTY 200, NIFTY 500, NIFTY 500, NIFTY MIDCAP 100, NIFTY MIDCAP 150, NIFTY MIDCAP 150, NIFTY MIDCAP 50, NIFTY PHARMA, NIFTY PHARMA
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
